Brief: Lyell Immunopharma Announces FDA Clearance Of Its IND For LYL845
06/10/2022 21:50
Oct 6 (Reuters) - Lyell Immunopharma Inc LYEL.O :
* LYELL IMMUNOPHARMA ANNOUNCES FDA CLEARANCE OF ITS IND FOR
LYL845, A TIL PRODUCT CANDIDATE ENHANCED WITH ITS NOVEL
EPIGENETIC REPROGRAMMING TECHNOLOGY FOR SOLID TUMORS
* LYELL IMMUNOPHARMA - PATIENT SCREENING FOR PHASE 1 TRIAL
FOR
LYL845 SET TO BEGIN OVER COMING MONTHS, AND INITIAL CLINICAL
DATA IS EXPECTED IN 2024
Source text for Eikon: ID:nGNX7L55NF
Further company coverage: LYEL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lyell Immunopharma
See all newsBrief: Lyell Immunopharma Says Additional Clinical Data And End-Of-Phase 1 FDA Meeting Expected In 2027
Lyell Immunopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Lyell Immunopharma, Inc. expected to post a loss of $2.08 a share - Earnings Preview
Brief: Lyell Immunopharma Q2 Operating Expenses USD 47.341 Million
Brief: Lyell Immunopharma Shows Updated Safety Data For Ronde-Cel In Patients With Large B-Cell Lymphoma